{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T18:33:06Z","timestamp":1762108386231,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clinre.2024.102465","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T01:16:09Z","timestamp":1726190169000},"page":"102465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Camrelizumab combined with transcatheter arterial chemoembolization for intermediate or advanced hepatocellular carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"48","author":[{"given":"Li","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaoping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.clinre.2024.102465_bib0001","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/S1590-8658(10)60507-5","article-title":"The changing pattern of epidemiology in hepatocellular carcinoma","volume":"42","author":"Nordenstedt","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clinre.2024.102465_bib0002","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study","volume":"4","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinre.2024.102465_bib0003","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2024.102465_bib0004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2024.102465_bib0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000367739","article-title":"Surgical and locoregional therapy of HCC: TACE","volume":"4","author":"Tsurusaki","year":"2015","journal-title":"Liver Cancer"},{"key":"10.1016\/j.clinre.2024.102465_bib0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"Lyu","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102465_bib0007","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clinre.2024.102465_bib0008","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinre.2024.102465_bib0009","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.2147\/OTT.S286169","article-title":"Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study","volume":"13","author":"Yuan","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clinre.2024.102465_bib0010","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2217\/imt-2020-0197","article-title":"Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma","volume":"12","author":"Yan","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clinre.2024.102465_bib0011","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-20-3136","article-title":"Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy","volume":"27","author":"Zhou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinre.2024.102465_bib0012","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","article-title":"The role of angiogenesis in hepatocellular carcinoma","volume":"25","author":"Morse","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinre.2024.102465_bib0013","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinre.2024.102465_bib0014","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2024.102465_bib0015","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102465_bib0016","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000503254","article-title":"Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti-PD-1\/PD-L1 and anti-CTLA-4 antibodies","volume":"8","author":"Kudo","year":"2019","journal-title":"Liv Cancer"},{"key":"10.1016\/j.clinre.2024.102465_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.clinre.2024.102465_bib0018","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2024.102465_bib0019","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"year":"2024","series-title":"EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization","author":"Lencioni","key":"10.1016\/j.clinre.2024.102465_bib0020"},{"key":"10.1016\/j.clinre.2024.102465_bib0021","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2019.01.027","article-title":"Combined locoregional-immunotherapy for liver cancer","volume":"70","author":"Greten","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102465_bib0022","article-title":"Targets for immunotherapy of liver cancer","author":"Greten","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102465_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.525","article-title":"Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): preliminary results from a phase I study of patients (pts) with liver limited hepatocellular carcinoma (HCC)","volume":"38","author":"Harding","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2024.102465_bib0024","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2012.02.011","article-title":"TACE with or without systemic therapy?","volume":"56","author":"Dufour","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102465_bib0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"10.1016\/j.clinre.2024.102465_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1536867X0800800102","article-title":"metan: fixed- and random-effects meta-analysis","volume":"8","author":"Harris","year":"2008","journal-title":"Stata J"},{"key":"10.1016\/j.clinre.2024.102465_bib0027","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2024.102465_bib0028","first-page":"116","article-title":"Clinical observation of camrelizumab therapy after TACE in the treatment of patients with advanced primary liver cancer","volume":"26","author":"Du","year":"2023","journal-title":"J Prac Hepatol"},{"key":"10.1016\/j.clinre.2024.102465_bib0029","first-page":"391","article-title":"TACE combined with camrelizumab for treatment of advanced hepatocellular carcinoma","volume":"19","author":"Yu","year":"2022","journal-title":"Chin J Interv Imaging Ther"},{"key":"10.1016\/j.clinre.2024.102465_bib0030","first-page":"557","article-title":"Clinical efficacy of ranvartinib and Camrelizumab combined with TACE in the treatment of advanced or unresectable hepatocellular carcinoma","volume":"41","author":"Zhu","year":"2022","journal-title":"J Southeast Univ (Medical Science Edition)"},{"key":"10.1016\/j.clinre.2024.102465_bib0031","article-title":"Apatinib plus camrelizumab with\/without chemoembolization for hepatocellular carcinoma: a real-world experience of a single center","volume":"11","author":"Ju","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinre.2024.102465_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.816198","article-title":"Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: a prospective, multi-center, real-world study","volume":"12","author":"You","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinre.2024.102465_bib0033","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12885-022-09451-1","article-title":"Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination","volume":"22","author":"Ju","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinre.2024.102465_bib0034","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.2147\/DDDT.S372276","article-title":"Predicting outcome in combination treatment of TACE and camrelizumab for advanced hepatocellular carcinoma: tumor hypervascularity and reactive cutaneous capillary endothelial proliferation","volume":"16","author":"Yin","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinre.2024.102465_bib0035","article-title":"Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a two-center retrospective study","volume":"12","author":"Sun","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinre.2024.102465_bib0036","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/JHC.S358658","article-title":"Safety and efficacy of transarterial chemoembolization and immune checkpoint inhibition with camrelizumab for treatment of unresectable hepatocellular carcinoma","volume":"9","author":"Zhang","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.clinre.2024.102465_bib0037","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/JHC.S400948","article-title":"The feasibility of TACE combined with TKIs plus PD-1 antibody for advanced HCC","volume":"10","author":"Sun","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.clinre.2024.102465_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1057560","article-title":"Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: a two-center propensity score matching study","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinre.2024.102465_bib0039","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-023-10519-8","article-title":"Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study","author":"Duan","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.clinre.2024.102465_bib0040","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1053\/jhep.2002.31354","article-title":"Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis","volume":"35","author":"Banares","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2024.102465_bib0041","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"year":"2016","series-title":"Joanna briggs institute reviewers'manual","key":"10.1016\/j.clinre.2024.102465_bib0042"},{"key":"10.1016\/j.clinre.2024.102465_bib0043","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1038\/s41388-020-1249-9","article-title":"Immune-based therapies for hepatocellular carcinoma","volume":"39","author":"Pinato","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.clinre.2024.102465_bib0044","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/15384047.2018.1529099","article-title":"The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study","volume":"20","author":"Yang","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clinre.2024.102465_bib0045","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820965587","article-title":"Efficacy and safety of transarterial chemoembolization combined with anlotinib for unresectable hepatocellular carcinoma: a retrospective study","volume":"19","author":"Guo","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.clinre.2024.102465_bib0046","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 Antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinre.2024.102465_bib0047","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinre.2024.102465_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081085","article-title":"Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC)","volume":"11","author":"Viveiros","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clinre.2024.102465_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124001864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124001864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:50:42Z","timestamp":1730530242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740124001864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2210740124001864"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102465","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Camrelizumab combined with transcatheter arterial chemoembolization for intermediate or advanced hepatocellular carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102465"}}